The pharmaceutical company Dr. Reddy’s Laboratories has entered into an exclusive partnership with South Korean company HK inno.N Corporation to commercialize their novel molecule Tegoprazan, indicated for gastrointestinal diseases, in India and selected emerging markets.
Under the partnership, HK inno.N will manufacture and supply Tegoprazan, while Dr. Reddy’s will be responsible for local clinical development, registration, commercialization and sales in the licensed territories. The agreement grants Dr. Reddy has exclusive rights to develop and commercialize Tegoprazan under its own brand in these markets for 10 years from initial commercial launch.
HK inno.N Corporation will receive an upfront royalty and be eligible for potential regulatory milestone payments and royalties on net product sales, said Dr. Reddy’s on Wednesday. Tegoprazan is approved in South Korea and China and in registration and clinical development in several countries worldwide, including the United States.
“Gastroenterology was a focus area for us. This collaboration is a multi-country agreement on a novel molecule that will address unmet needs in India and emerging markets as we continue our commitment to patients and our innovation agenda,” said MV Ramana, CEO of Dr. Reddy, Branded Markets (India and Emerging Markets). in a release.
The commercial strengths of Dr. Reddy’s make it the ideal partner to commercialize the novel molecule in these territories, said Dal-Won Kwak, CEO of HK inno.N.
